Nautilus Biotechnology Q3 net loss widens 15% to $15.64 million
Bitget2026/10/27 10:03- Nautilus Biotechnology’s third-quarter 2026 net loss widened 15% year over year to $15.64 million.
- Revenue reached $234,000, while operating expenses rose 10% year over year to $16.95 million.
- Cash, cash equivalents and investments totaled $114.3 million at September 30, 2026.
- Following quarter-end, Nautilus joined the ARPA-H-funded SEEDS consortium, expecting up to $6 million to study Alzheimer’s disease and cancer proteoforms.
- Management maintained planned instrument availability in mid-2027, with development advancing toward twenty proteoform assays through mid-2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After the sharp decline in tech stocks, the White House suddenly canceled the top tech advisor meeting the following day.
The White House has canceled the previously scheduled President’s Council of Advisors on Science and Technology meeting, which was set for Friday and includes prominent tech leaders such as Nvidia CEO Jensen Huang and Meta CEO Mark Zuckerberg. The Department of Energy's meeting page briefly listed November 13 as the new meeting date, but the agency later sent an email retracting this information. Currently, the specific date for rescheduling the meeting remains unclear.
Turtle Creek Asset Management Reports Sale of $347,850 in Jeld-Wen Common Shares
GLOBALFOUNDRIES Director Ganesh Moorthy Reports $93,687.50 Share Acquisition
Crypto prices
More
